11.20
43.26%
-8.54
After Hours:
11.40
0.20
+1.79%
EyePoint Pharmaceuticals Inc stock is currently priced at $11.20, with a 24-hour trading volume of 9.64M.
It has seen a -43.26% decreased in the last 24 hours and a -44.77% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $20.23 pivot point. If it approaches the $17.67 support level, significant changes may occur.
Previous Close:
$19.74
Open:
$13.89
24h Volume:
9.64M
Market Cap:
$583.34M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-3.9716
EPS:
-2.82
Net Cash Flow:
$-1.61M
1W Performance:
-36.47%
1M Performance:
-44.77%
6M Performance:
+46.79%
1Y Performance:
+71.25%
EyePoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Name
EyePoint Pharmaceuticals Inc
Sector
Industry
Phone
617-926-5000
Address
480 Pleasant Street, Suite B300, Watertown, MA
EyePoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-22-24 | Initiated | JP Morgan | Overweight |
Nov-02-23 | Initiated | Mizuho | Buy |
Apr-21-23 | Initiated | Robert W. Baird | Outperform |
Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
Mar-01-21 | Initiated | Cowen | Outperform |
Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
Nov-04-19 | Resumed | Laidlaw | Buy |
Sep-12-19 | Initiated | Guggenheim | Buy |
View All
EyePoint Pharmaceuticals Inc Stock (EYPT) Latest News
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
GlobeNewswire Inc.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire Inc.
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
GlobeNewswire Inc.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Critical Insights From EyePoint Pharmaceuticals Analyst Ratings: What You Need To Know
Benzinga
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
Zacks Investment Research
EyePoint Pharmaceuticals Inc Stock (EYPT) Financials Data
EyePoint Pharmaceuticals Inc (EYPT) Revenue 2024
EYPT reported a revenue (TTM) of $46.02 million for the quarter ending December 31, 2023, a +11.14% rise year-over-year.
EyePoint Pharmaceuticals Inc (EYPT) Net Income 2024
EYPT net income (TTM) was -$70.80 million for the quarter ending December 31, 2023, a +30.77% increase year-over-year.
EyePoint Pharmaceuticals Inc (EYPT) Cash Flow 2024
EYPT recorded a free cash flow (TTM) of -$1.61 million for the quarter ending December 31, 2023, a +97.61% increase year-over-year.
EyePoint Pharmaceuticals Inc (EYPT) Earnings per Share 2024
EYPT earnings per share (TTM) was -$1.82 for the quarter ending December 31, 2023, a +33.33% growth year-over-year.
About EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials. It also offers Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. In addition, the company has developed DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. Further, it develops YUTIQ shorter-actinguveitis for the treatment of posterior segment uveitis; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Additionally, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It sells its products primarily in the United States and Europe. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, and Enigma Therapeutics Limited. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Cap:
|
Volume (24h):